Related Experiment Video
Updated: Jul 27, 2025
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.7K
Toll-like Receptor 4 Inflammatory Perspective on Doxorubicin-Induced Cardiotoxicity.
Natticha Sumneang1,2, Pongpan Tanajak3, Thura Tun Oo4
1Department of Medical Science, School of Medicine, Walailak University, Nakhon Si Thammarat 80160, Thailand.
Molecules (Basel, Switzerland)
|June 10, 2023
Summary
Doxorubicin (Dox) chemotherapy causes heart damage, partly via Toll-like receptor 4 (TLR4) signaling and cardiac inflammation. Targeting TLR4 may offer new strategies to prevent Dox-induced cardiotoxicity.
Area of Science:
- Cardiology
- Oncology
- Immunology
Background:
- Doxorubicin (Dox) is a vital chemotherapy agent, but its use is limited by cardiotoxicity.
- Dox-induced cardiotoxicity mechanisms remain incompletely understood, lacking specific therapeutic guidelines.
- Cardiac inflammation is recognized as a key contributor to Dox-induced cardiotoxicity.
Purpose of the Study:
- To review evidence linking the Toll-like receptor 4 (TLR4) signaling pathway to Dox-induced cardiotoxicity.
- To discuss the impact of TLR4 signaling on cardiac inflammation and subsequent cardiotoxicity.
- To explore potential therapeutic strategies targeting TLR4 for mitigating Dox-induced cardiotoxicity.
Main Methods:
- Comprehensive literature review of studies investigating Doxorubicin effects on the heart.
- Analysis of research on the Toll-like receptor 4 (TLR4) signaling pathway in cardiac inflammation models.
- Synthesis of evidence from various models of Dox-induced cardiotoxicity.
Main Results:
- The Toll-like receptor 4 (TLR4) signaling pathway is demonstrably involved in Dox-induced cardiac inflammation.
- TLR4 activation significantly contributes to the development and progression of Dox-induced cardiotoxicity.
- Evidence supports a strong correlation between TLR4-mediated inflammation and cardiac damage from Doxorubicin.
Conclusions:
- The TLR4 signaling pathway plays a critical role in Doxorubicin-induced cardiac inflammation.
- Understanding TLR4's role is crucial for developing targeted therapies against Dox-induced cardiotoxicity.
- Targeting TLR4 presents a promising avenue for future therapeutic interventions to protect the heart during chemotherapy.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
641
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
641
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
12
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12
01:30Cardiomyopathy II: Dilated Cardiomyopathy
12
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
12
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
17
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
17
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
29
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
29
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
469
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
469